Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
SYDNEY & LOS ANGELES, May 17, 2022--Imugene Limited and City of Hope's first patient was dosed in a clinical trial evaluating the safety of new cancer-killing virus CF33-hNIS VAXINIA.
New clinical trial supply agreement with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ., USA for Phase 2 clinical study (nextHERIZON) in HER-2 positive gastric or gastroesophageal junction adenocarcinomasnextHERIZON will assess HER-Vaxx in combination with chemotherapy or pembrolizumab in patients with HER-2 positive gastric cancer that have failed trastuzumab SYDNEY, Australia, March 14, 2022 (GLOBE NEWSWIRE) -- Imugene (ASX: IMU) today announced a new clinical trial collaboration and s